	US 12,150,929 B2
	Compositions and methods for the treatment of depression
Mark Schmidt, Antwerp (BE); Vanina Popova, Nijlen (BE); Adam Savitz, Greenwich, CT (US); Rama Melkote, Basking Ridge, NJ (US); Wayne C. Drevets, Rancho Santa Fe, CA (US); Srihari Gopal, Belle Mead, NJ (US); Darrel Pemberton, Oud Turnhout (BE); Chakradhar Lagishetty, King of Prussia, PA (US); and Iva Kezic, Antwerp (BE)
Assigned to Janssen Pharmaceuticals, Inc., Titusville, NJ (US)
Filed by Janssen Pharmaceuticals, Inc., Titusville, NJ (US)
Filed on Jan. 31, 2024, as Appl. No. 18/428,937.
Application 18/428,937 is a continuation of application No. 18/188,894, filed on Mar. 23, 2023, granted, now 11,998,525.
Application 18/188,894 is a continuation of application No. 17/670,123, filed on Feb. 11, 2022.
Application 17/670,123 is a continuation of application No. 17/307,858, filed on May 4, 2021, granted, now 11,266,627, issued on Mar. 8, 2022.
Prior Publication US 2024/0189274 A1, Jun. 13, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/40 (2006.01); A61K 9/00 (2006.01); A61P 25/24 (2006.01)

CPC A61K 31/40 (2013.01) [A61K 9/0056 (2013.01); A61P 25/24 (2018.01)]

19 Claims

1. A method for treating major depressive disorder in a human patient, comprising administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof, wherein the patient had an inadequate response to other antidepressant therapy prior to treatment with the aticaprant, or a pharmaceutically acceptable salt thereof.